Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Antibacterial Drugs Market to Hit $35.6B by 2022

By GBI Research | January 24, 2017

Antibacterial drugs market will hit $35.6 billion by 2022, as efforts increase to tackle antimicrobial resistance, says GBI Research.

The antibacterial drugs market is set to grow from $27.7 billion in 2015 to $35.6 billion by 2022, representing a compound annual growth rate of 3.97%, according to business intelligence provider GBI Research.

The company’s latest report states that emerging companies and the approvals of new products will drive this growth, along with the continued success of the established marketed products Infanrix, which vaccinates against diphtheria, tetanus and pertussis, and Augmentin, which is amoxicillin sodium and clavulanate potassium.

Thomas Jarratt, Associate Analyst for GBI Research, explains: “In an attempt to tackle antimicrobial resistance, many companies are investing in the development of products active against bacteria that are known to be resistant to established classes of antibacterials. The use of protein synthesis inhibitors, for example, is expected to increase dramatically over the forecast period as a result of their effectiveness in treating drug-resistant bacterial infections.”

With many protein synthesis inhibitors now off-patent, and with bacteria having developed resistance to a wide range of these drugs, GBI Research believes several of the pipeline drugs for the next-generation of protein synthesis will be approved and enter the market within the forecast period, and will benefit from the commercial focus on treating drug-resistant infections. These include Solithera (solithromycin), Arikace (amikacin sulfate), Cadazolid (cadazolid), and Plazomicin (plazomicin sulfate).

Jarratt continues: “Despite this influx of new protein synthesis inhibitors and the release of several new cell-wall synthesis inhibitors, vaccines will still be the leading revenue generating drugs in the antibacterial drugs market. Indeed, the lack of biosimilars for antibacterial vaccines means that generic competition does not impact on sales as it does for other types of drugs, and many developed countries implement schedules for vaccines preventing certain indications.

“Merck’s blockbuster Prevnar, for example, has benefited greatly from this, and its efficacy in infants for the prevention of 13 serotypes of streptococcus pneumonia, the causative agent in pneumonia, has led to widespread global usage in vaccination schedules, culminating in very high revenue.”

(Source: GBI Research)

Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!


Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50